Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients With Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma

Trial Profile

Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients With Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma

Discontinued
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs DCR MYC (Primary)
  • Indications Lymphoma; Multiple myeloma; Neuroendocrine tumours; Non-Hodgkin's lymphoma; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Dicerna Pharmaceuticals
  • Most Recent Events

    • 03 Aug 2017 Status changed from active, no longer recruiting to discontinued as per the sponsor decision
    • 25 Jul 2017 Planned End Date changed from 1 Dec 2016 to 31 Aug 2017.
    • 25 Jul 2017 Planned primary completion date changed from 1 Dec 2016 to 31 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top